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Abstract 30 
Introduction.  Difficult Gram-negative infections are increasingly treated with new -31 
lactamase inhibitor combinations e.g. ceftazidime/avibactam. Disturbingly, mutations in KPC 32 
carbapenemases can confer ceftazidime/avibactam resistance, sometimes selected in 33 
therapy.  We explored whether this risk extended to AmpC- and ESBL- enzymes. Materials 34 
and Methods. Mutants were selected by plating AmpC-derepressed strains, ESBL 35 
producers and ceftazidime-susceptible controls on agar containing ceftazidime + avibactam, 36 
1 or 4 mg/L.  MICs were determined by CLSI agar dilution; WGS was by Illumina 37 
methodology.  Results Using 2x MIC of ceftazidime + 1 mg/L avibactam, mutants were 38 
selected from all strain types at frequencies of 10-7 - 10-9. Rates diminished to <10-9 with 4 39 
mg/L avibactam or higher MIC multiples, except with AmpC-derepressed 40 
Enterobacteriaceae.  Characterised mutants (n=10, MICs 4-64 mg/L) of AmpC-derepressed 41 
strains had modifications in ampC, giving Arg168Pro/HIs, Gly176Arg/Asp, Asn366Tyr or 42 
small deletions around positions 309-314. Mutants of ESBL producers (n=20; MICs 0.5-16 43 
mg/L) mostly had changes affecting permeability, efflux or -lactamase quantity; only one 44 
had an altered -lactamase, with an Asp182Tyr substitution in CTX-M-15, raising the 45 
ceftazidime/avibactam MIC but abrogating other cephalosporin resistance.  Mutants of 46 
ceftazidime-susceptible strains were not sequenced, but phenotypes suggested altered drug 47 
accumulation or, for Enterobacter cloacae only, AmpC derepression.  In further experiments, 48 
avibactam reduced, but did not abolish, selection of AmpC-derepressed Enterobacteriaceae 49 
by ceftazidime. Conclusions.  Most mutants of AmpC-derepressed Enterobacteriaceae had 50 
structural mutations in ampC; those of ESBL producers mostly had genetic modifications 51 
outside -lactamase genes, commonly affecting uptake efflux or -lactamase quantity.  The 52 
clinical significance of these observations remains to be determined. 53 
54 
Introduction 55 
Avibactam is the first diazabicyclooctane -lactamase inhibitor to enter clinical use, 56 
formulated with ceftazidime and now licensed in both the US and the EU. An 57 
aztreonam/avibactam combination is in advanced development; development of a ceftaroline 58 
combination was pursued into Phase II but is now in abeyance.1   Avibactam inhibits Class A 59 
-lactamases, including ESBLs and KPC types, as well as Class C (AmpC) types.2 Inhibitory 60 
activity against Class D -lactamases is variable but, few of these are potent ceftazidimases.  61 
Metallo- (Class B) enzymes evade inhibition.  As with all -lactamase inhibitor combinations, 62 
activity also depends on the amount of lactamase, the underlying spectrum of the 63 
partner-lactam and the permeability and efflux traits of the target strain.3,4 64 
Single amino acid substitutions can reduce binding of clavulanate and penicillanic 65 
acid sulphones by TEM and SHV penicillinases,5 but in-therapy selection of sequence 66 
variants of these enzymes is very rare.6,7 Less is yet known on the potential of avibactam 67 
combinations to select resistance.  In-vitro studies with ceftaroline/avibactam8 yielded: (i) a 68 
single mutant of CTX-M-15 enzyme with a Lys237Gln substitution, and (ii) 69 
ceftaroline/avibactam-resistant mutants of AmpC-derepressed Enterobacter with deletions in 70 
the -loop of AmpC, with  Asn366His/Ile substitutions in AmpC or with porin modifications. 71 
The CTX-M-15 mutant conferred resistance to ceftaroline/avibactam but lost the ability of 72 
classical CTX-M-15 to cause resistance to other oxyimino-cephalosporins; the AmpC 73 
mutants were associated with broad resistance. We failed to select stable resistance to 74 
ceftaroline/avibactam in Enterobacteriaceae with other ESBLs besides CTX-M-15 or in those 75 
with KPC lactamase. 8 More recently, in-vitro and clinical selections of 76 
ceftazidime/avibactam-resistant mutants of Enterobacteriaceae with KPC carbapenemases 77 
have been described.  Several mutations were seen in the laboratory mutants, mostly re-78 
configuring the -loop.9  These alterations included Asp179Tyr, which has since been 79 
selected, during ceftazidime/avibactam therapy, in clinical mutants.10  Its effect is to increase 80 
binding of ceftazidime,11 protecting the KPC enzyme from inactivation by avibactam. Such 81 
mutants show only small MIC rises for avibactam combinations other than 82 
ceftazidime/avibactam and often have reduced resistance to meropenem and aztreonam.9,10  83 
Clinical selection of reduced susceptibility, with the ceftazidime/avibactam MIC rising from 1 84 
to 8 mg/L, was also described in a Klebsiella pneumoniae with OXA-48 and CTX-M-14. This 85 
was associated with Pro170Ser and Thr264Ileu mutations in the CTX-M-14 enzyme;12 OXA-48, 86 
which lacks ceftazidimase activity, remained unchanged.   87 
These observations led us to undertake selection studies with ceftazidime/avibactam, 88 
investigating a wide range of ESBLs and AmpC enzymes 89 
 90 
Materials and Methods 91 
Test strains 92 
The test strains are detailed in Table 1 and were either reference organisms, isolates from 93 
survey collections.13,14.  Work centred on Escherichia coli, K. pneumoniae, Enterobacter 94 
cloacae and Citrobacter freundii, as the major opportunistic Enterobacteriaceae and on 95 
TEM, SHV, CTX-M-15 and AmpC as the prevalent lactamases of concern.   96 
-Lactamase types were initially identified from phenotypes and PCR, but later 97 
confirmed by WGS.  Controls for MIC testing comprised E. coli ATCC 25922, E. coli ATCC 98 
35218 and K. pneumoniae ATCC 700603. 99 
 100 
Antibiotics 101 
Avibactam was provided by AstraZeneca (Wilmington, DE, USA), as were ceftazidime and 102 
ceftaroline; other antimicrobials were obtained from Sigma (Poole, UK), except ertapenem 103 
(Merck Sharp & Dohme, Hoddesdon, UK) and meropenem (AstraZeneca, Alderley Park, 104 
UK). 105 
 106 
Single step mutant selection   107 
Selection was undertaken as previously described for ceftaroline/avibactam.8 Briefly c. 109 108 
cfu from an overnight broth culture were spread on Mueller-Hinton agar 109 
(Thermofisher/Oxoid, Basingstoke, UK) containing ceftazidime/avibactam (fixed 1 or 4 mg/L 110 
concentration) at 2-16 x the MIC found previously by CLSI agar dilution.  Colonies were 111 
counted after overnight incubation, and representatives retained for MIC determination and 112 
sequencing.  Dilutions of the same overnight nutrient broth cultures were serially diluted and 113 
spread on to antibiotic-free Mueller-Hinton agar to provide a viable count, as a denominator 114 
for calculation of mutation frequencies. 115 
   116 
Multi-step selection using -lactamase producers 117 
Inocula of 108 cfu were added to 10-mL amounts of nutrient broth containing 118 
ceftazidime/avibactam (with avibactam at 1 or 4 mg/L) at the ceftazidime/avibactam MICs 119 
found previously on agar with the same avibactam concentration, but otherwise by standard 120 
CLSI methodology,, and incubated up to 48 h.8 This was repeated sequentially, each time 121 
doubling the ceftazidime concentration but keeping the avibactam concentration unchanged.   122 
 123 
Selectivity for AmpC-derepressed mutants 124 
Like other oxyimino-cephalosporins, ceftazidime can select AmpC-derepressed mutants 125 
from AmpC-inducible populations.15 To test how avibactam might affect this phenomenon we 126 
plated c. 109 cfu of ceftazidime-susceptible (i.e., wild-type, AmpC-inducible, MIC <2 mg/L) 127 
cells of E. cloacae or C. freundii on to Mueller-Hinton agar with ceftazidime at 8 x MIC with 128 
or without 1 or 4 mg/L avibactam.   After overnight incubation the colonies were counted and 129 
mutant frequencies calculated relative to the viable counts contained in the inocula. 130 
 131 
MIC determinations 132 
MICs were measured by CLSI agar dilution16 for ceftazidime and for -lactams in 133 
combination with β-lactamase inhibitors at the specified concentrations: 134 
ceftazidime/avibactam 1 and 4 mg/L, ceftazidime/cloxacillin 100 mg/L, 135 
ceftazidime/clavulanate 4 mg/L, ceftazidime/ tazobactam 4 mg/L, cefotaxime, cefepime, 136 
piperacillin/tazobactam 4 mg/L, ertapenem, meropenem, gentamicin and ciprofloxacin.  137 
 138 
Genomic sequencing and bioinformatics analysis 139 
Parent and mutant DNA were fragmented and tagged for multiplexing using the NexteraXT 140 
library preparation Kits (Illumina, Cambridge, UK) and sequenced on an Illumina HiSeq 141 
platform to produce 2x100 bp reads. Reads were assembled de novo using VelvetOptimiser 142 
software (http://www.vicbioinformatics.com/software.velvetoptimiser.shtml) with k-mer values 143 
from 55 to 75. Thepresence of β-lactamase variants was confirmed by BLAST searches, 144 
using the newly assembled genomes as query sequences against a reference database 145 
downloaded from the NCBI β-lactamase data (https://www.ncbi.nlm.nih.gov/pathogens/beta-146 
lactamase-data-resources) resources. 147 
Genomic alterations in mutants were identified as previously described.17 sequencing 148 
reads for mutants were mapped to the de-novo assembled genome of the corresponding 149 
parent using Bowtie2 (http://bowtie-bio.sourceforge.net/bowtie2),  and variants were called  150 
with Samtools with default paramters.18 The variant calling files thereby generated were then 151 
parsed line by line to determine apparent alterations, with the accuracy of these predictions 152 
assessed based on read depth and mapping quality as described previously.17 Sequences 153 
flanking confirmed alterations for 2-5 Kb on either side were extracted from the parent 154 
assemblies and manually inspected for gene structure and functional annotation with Blast 155 
searches so as to determine whether the detected changes were located in an open reading 156 
frame, promoter or intergenic region. Changes within structural genes were confirmed by 157 
aligning the protein-encoding sequences extracted from the parent and mutant assemblies. 158 
In high throughput sequencing, reads are randomly sampled, meaning that the number of 159 
reads for any gene or gene fragment reflectsits copy number:  We therefore counted the 160 
number of reads that mapped to  the β-lactamase genes relative to those fo ther single-copy 161 
chromosomal gyrA and parC genes, thereby assessing whether the β-lactamase genes had 162 
been amplified in the mutants.  Parent and mutant sequencing data are deposited in the 163 
European Nucleotide Archive under study number PRJEB27344 (www.ebi.ac.uk/ena). 164 
 165 
Results 166 
Mutant selection frequencies 167 
Mutants were obtained from most strains, including -lactamase-negative controls, when 168 
using ceftazidime/avibactam 1 mg/L at 2 x MIC, with frequencies of 10-7 to 10-9 (Table 1).  169 
Mutant frequencies were much reduced at higher MIC multiples or with 4 mg/L avibactam in 170 
the selective media.  With 8- or 16-fold MIC multiples, mutants were obtained only from 171 
strains with stably derepressed AmpC; none was detected from ESBL producers or controls, 172 
even when the avibactam concentration was only 1 mg/L.  Attempts to ‘train’ highly resistant 173 
mutants by multi-step procedures in broth were unsuccessful, with few mutants obtained; 174 
again mostly from strains with stably derepressed AmpC -lactamases. 175 
 176 
Mutants of AmpC derepressed strains 177 
MICs were determined for 53 mutants selected from AmpC-derepressed E. cloacae or C. 178 
freundii. The MICs of ceftazidime/avibactam 4 mg/L rose from 0.5-2 mg/L for the parent 179 
strains to 4-64 (mostly 8-16) mg/L for the mutants; in 23/53 cases the values for the mutants 180 
were >8+4 mg/L, exceeding the CLSI/EUCAST breakpoint.  MICs of ceftazidime combined 181 
with cloxacillin 100 mg/L (which inhibits AmpC) also were widely, though not universally, 182 
raised: MICs of ceftaroline/avibactam rose little, generally only from 0.25-2 mg/L to 1-2 mg/L.  183 
Shifts in the MICs of other lactams were erratic: some mutants showed rises in cefotaxime 184 
and cefepime MICs whereas others showed falls. Likewise, a few mutants showed increases 185 
in ertapenem MIC, but falls were commoner. 186 
This diversity is illustrated in Table 2 for the 10 mutants of AmpC-derepressed E. 187 
cloacae and C. freundii selected for WGS. All proved to have modifications in ampC, 188 
resulting in amino acid substitutions, including Arg168Pro (three representatives), Arg168His 189 
(two representatives), Gly176Arg/Asp (one representative each) Asn366Tyr (one 190 
representative) or two- to four- amino acid deletions around positions 309-314 (two 191 
representatives).  The Arg168Pro substitution was associated with reduced resistance to all 192 
cephalosporins, in both E. cloacae and C. freundii along with the complete loss of synergy 193 
between avibactam and both ceftazidime and ceftaroline, whereas Arg168His and 194 
Gly176Arg/Asp were associated with retention of broad cephalosporin resistance and 195 
ceftaroline/avibactam synergy coupled with markedly reduced ceftazidime/avibactam 196 
synergy. 197 
 198 
Characterisation of selected mutants: ESBL producers 199 
Among 63 mutants of nine ESBL producers (the tenth failed to yield any mutants), only 12 200 
achieved resistance to ceftazidime/avibactam as defined by CLSI, with MICs of 16+4 or 201 
32+4 mg/L.  All these 12 were selected from the same parent, E. coli J53-1 with TEM-10 202 
ceftazidimase. The ceftazidime/avibactam MICs for other mutants were raised, but with 203 
values <8+4 mg/L.  MICs for 20 mutants selected to represent phenotype diversity are 204 
shown in Table 3, along with details of the genetic modifications revealed by WGS. 205 
 Most mutants of ESBL producers had sequence changes in genes related to 206 
permeability, efflux or -lactamase expression, not in -lactamase coding genes.  Thus, 7/20 207 
had modifications in ompR/envZ, which regulates expression of porins OmpC and OmpF;20 208 
2/20 had identical alterations in acrAB efflux gene components; and 9/20 either yielded 209 
increased reads of -lactamase genes relative to gyrA and parC during WGS, implying gene 210 
amplification, or had sequence changes upstream of -lactamase genes that putatively 211 
might increase their expression, though this was not investigated by experiment.   Almost all 212 
these mutants of ESBL producers showed broad upward rises for -lactam MICs, including 213 
other inhibitor combinations besides ceftazidime/avibactam.  A representative (‘Mutant 5’) of 214 
the group of E. coli J53-1 TEM-10 mutants with ceftazidime/avibactam MICs of 16+4 mg/L 215 
(i.e. the most-resistant mutants selected from ESBL producers, see above) had changes in 216 
both envZ and upstream of blaTEM; MICs of 4+4 mg/L were recorded for Mutants 2, 3 and 4 217 
of the same parent, and these only had the lesion upstream of blaTEM, not that in envZ. 218 
Just one of the 20 mutants sequenced – E. coli EO 553 Mutant 3 – had a lesion in its 219 
ESBL-encoding gene, leading to an Asp182Tyr substitution in CTX-M-15.  Compared with its 220 
parent, this mutant lost resistance to ceftaroline, cefotaxime and cefepime, and the 221 
ceftazidime MIC was reduced two-fold from 32 to 16 mg/L.   Synergy was completely lost 222 
between ceftazidime and clavulanate or tazobactam whilst the ceftazidime/avibactam MIC 223 
rose 8-fold, from 0.25 mg/L to 2 mg/L. 224 
One further mutant – Mutant 8 of K. pneumoniae Mei 838 – had a lesion in mdrA, 225 
which encodes penicillin-binding protein 2. This may act as a secondary target for 226 
diazabicyclooctanes, though this effect is much weaker for avibactam than for the 227 
developmental analogues nacubactam and zidebactam.21,22 The significance of this lesion is 228 
difficult to judge. 229 
Finally, several mutants had changes in proteins with no obvious link to -lactam or 230 
diazabicyclooctane action, including (i) aspartate semialdehyde dehydrogenase (Mutant 7 of 231 
K. pneumoniae Mei 838), (ii) 4-cytidine 5-diphospho-2-C-methyl D erythritol kinase and 232 
putative sulphate transporter (both in Mutant 8 of K. pneumoniae Mei 838) and (iii) the DNA-233 
binding protein HLP-II pleiotropic regulator (Mutant 14 of K. pneumoniae Mei 254). 234 
 235 
Mutants from control Enterobacteriaceae lacking ceftazidime resistance 236 
Mutants of ceftazidime-susceptible E. coli and K. pneumoniae were obtained under selection 237 
with ceftazidime/avibactam 1 mg/L, though not ceftazidime/avibactam 4 mg/L (Table 1). 238 
MICs of ceftazidime/avibactam 1 mg/L rose from 0.06 to 0.25 mg/L for the parent strains to 239 
0.5-4 mg/L for the mutants, whilst those of ceftazidime/avibactam 4 mg/L rose from 0.015-240 
0.25 mg/L to 0.12-2 mg/L.  These shifts were accompanied by small, generalised, rises in 241 
the MICs of other -lactams and inhibitor combinations and – often – ciprofloxacin.  Given 242 
this spectrum, permeability or efflux mechanisms are likely, and these were not pursued 243 
further.  244 
Similar small but broad MICs shifts were seen for 2/12 characterised mutants of the 245 
AmpC-inducible Enterobacter strain LN07013 selected with low MIC multiples of 246 
ceftazidime/avibactam 1 mg/L. However, 10/12 mutants had antibiograms suggesting 247 
AmpC-derepression, with high-level resistance to ceftazidime, cefotaxime, ceftaroline and 248 
piperacillin/tazobactam (MICs rising from <1 mg/L to >128 mg/L) but not to cefepime or 249 
carbapenems.  Despite selection with ceftazidime/avibactam, ceftazidime resistance 250 
continued to be largely reversed by avibactam, with the MIC falling from >128 mg/L for the 251 
unprotected cephalosporin to 2 mg/L with 1 mg/L avibactam and  to 0.5-2 mg/L with 4 mg/L 252 
avibactam or  to 1-8 mg/L with 100 mg/L cloxacillin.  253 
These observations led us to investigate the effect of avibactam on the selectivity of 254 
ceftazidime for AmpC-derepressed mutants from AmpC-inducible population of E. cloacae 255 
and C. freundii.  We plated five AmpC-inducible, ceftazidime-susceptible strains of each of 256 
these species on to agar with ceftazidime alone or with avibactam at 1 or 4 mg/L, always at 257 
8 x MIC.  Large numbers of colonies were recovered on plates containing ceftazidime alone, 258 
indicating mutation frequencies of 10-6 to 10-7, as is typical for these species.23 With 259 
avibactam at 1 mg/L, the numbers of colonies that grew were reduced by >75% in all cases 260 
and, for 8/10 strains, fell below the detection limit of 10-9; with avibactam at 4 mg/L, the 261 
mutant frequency fell below 10-9 for 9/10 strains. 262 
  263 
Discussion 264 
Mutational resistance to ceftazidime/avibactam has become a concern in respect of isolates 265 
with KPC carbapenemases, with reports of resistance emerging during therapy as well as in 266 
vitro.9,10  In the light of this concern we explored whether ceftazidime/avibactam could also 267 
select resistant mutants from AmpC-derepressed Enterobacteriaceae and ESBL producers; 268 
the work followed a similar previous study for ceftaroline/avibactam.8 We included common 269 
and representative ESBLs, specifically CTX-M-15, as the most prevalent type; CTX-M-1,  as  270 
common from animal isolates; SHV-2 and -5 as major ESBL mutants  of SHV-1 and TEM-10 271 
as a ceftazidimase-type ESBL.  E. cloacae and C. freundii were prioritsed as the major 272 
species where high-level expression AmpC is a resistance issue.  Clearly there are further 273 
enzymes that merit investigation in the future, notably including Group 9 CTX-M- types 274 
(CTX-M-9 or -14), which are globally frequent, and broad-spectrum TEM ESBLs (e.g. CTX-275 
M-3). 276 
 Unlike for KPC carbapenemases, where we found much higher mutation frequencies 277 
to ceftazidime/avibactam than to ceftaroline/avibactam,8,9 the present data substantially 278 
mirror those obtained with ceftaroline/avibactam, with (i) low mutation frequencies (<10-8 at 279 
above 2 x MIC), particularly when selection was done with 4 mg/L avibactam, (ii) with mostly 280 
small rises in ceftazidime/avibactam MICs, rather than frank resistance and (iii) with most 281 
emerging resistance seen among AmpC derepressed strains rather than those with ESBLs.  282 
 Critically, and also in keeping with the previous ceftaroline/avibactam work, we found 283 
that the mutants of AmpC derepressed strains typically had changes within ampC whereas 284 
mutants derived from ESBL producers largely had mutations affecting efflux, permeability or, 285 
putatively, -lactamase quantity. Nevertheless, there were differences: hot spots for 286 
mutations associated here with ceftazidime/avibactam non-susceptibility in AmpC 287 
hyperproducers were amino acids 168, 176, 309-314 and 366; those conferring 288 
ceftaroline/avibactam resistance were around the  loop (amino acids 213-226) or, again, 289 
residue 366.    Mutations at Arg168 – the site most often affected in this study – had differing 290 
effects: Arg168Pro reduced resistance to all cephalosporins and abrogated synergy between 291 
avibactam and both ceftazidime and ceftaroline.  This behaviour would be compatible with 292 
loss of affinity for avibactam, though this was not investigated biochemically. On the other 293 
hand, Arg168His (and Gly176Arg/Asp) raised ceftazidime/avibactam MICs but had little 294 
effect on cephalosporin resistance overall or on synergy between ceftaroline and avibactam 295 
– behaviours that are more compatible with the mutation conferring increased affinity for 296 
ceftazidime.  The substitutions were all at conserved positions, with a caveat that the 297 
background variation among the primary sequences of AmpC β-lactamases from E. cloacae 298 
was about 40% in one study.24  Asn366 (designated as Asn346 after discounting the 20-299 
amino acid signal peptide) has previously been described as a key residue for avibactam 300 
binding.24  The deletions around positions 309–314 observed here are in helix H10, close to 301 
the enzyme active site, and at the location where a 6-amino-acid deletion in clinical isolate E. 302 
cloacae CHE was associated with expansion of the enzyme’s activity and diminished 303 
susceptibility to avibactam combinations.19.   304 
 The sole mutant of an ESBL enzyme selected here was an Asp185Tyr variant of 305 
CTX-M-15.  This change was associated with the reduction or loss of resistance to other 306 
cephalosporins besides ceftazidime.  It seems unlikely that a mutant with such a narrowed 307 
resistance spectrum would be successful in evolutionary terms, implying little public health 308 
risk. Similar points were made previously in respect of a Lys237Gln mutant selected with 309 
ceftaroline/avibactam:8 compared with its parent organism this gained ceftaroline/avibactam 310 
resistance but lost resistance to other oxyimino-cephalosporins, including ceftazidime.  The 311 
other mutants selected in the present study from ESBL producers largely had efflux or 312 
permeability modifications, or had mutations and amplifications suggesting increased 313 
lactamase expression - a known general correlate with reduced susceptibility to β-314 
lactam/lactamase inhibitor combinations.4 315 
 Mutants selected from cephalosporin-susceptible AmpC and ESBL-negative E. coli 316 
and K. pneumoniae only showed small increases in ceftazidime/avibactam MICs and were 317 
not characterised in detail.  Again, however, their antibiograms suggested permeation- or 318 
efflux-related changes.  By contrast, most of the E. cloacae mutants had antibiograms 319 
suggesting AmpC derepression.  Although avibactam inhibits this enzyme, MICs of 320 
ceftazidime/avibactam for AmpC derepressed organisms are not quite so low as for 321 
inducible ones and there appears to be a small concentration window (as e.g. with 322 
cefepime)25 in which derepressed mutants may be selected, though these remain 323 
susceptible to ceftazidime/avibactam at breakpoint in the absence further changes to ampC 324 
itself 325 
 Only clinical experience will show whether the present observations have clinical 326 
significance.  Overall, they suggest that the potential for emerging resistance 327 
ceftazidime/avibactam is greater with AmpC producers than ESBL producers.  Thus far we 328 
are unaware of any reports of emerging resistance during clinical use against AmpC 329 
producers. There is a single report12 of emerging resistance in a pneumonia patient, with a 330 
K. pneumoniae producing OXA-48 carbapenemase together with CTX-M-14, an ESBL not 331 
studied here. The patient was treated first with ceftazidime plus colistin and later, after the 332 
ceftazidime MIC had risen from 4 to >256 mg/L, with ceftazidime/avibactam plus 333 
meropenem. During this latter phase of therapy the ceftazidime/avibactam MIC rose from 1 334 
to 8 mg/L and the CTX-M-14 enzyme acquired Pro170Ser and Thr264Ile substitutions, whilst 335 
the OXA-48 carbapenemase remained unaltered.  This one case must, however, be set 336 
against the clinical trials, where ESBL producers were well represented, without emerging 337 
resistance;26-28  these support our view that the selection risk with ESBL producers is low 338 
whereas that with AmpC-derepressed organisms will only be clarified by clinical experience.   339 
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Table 1. Frequencies of single step mutants selected on agar containing MIC multiples of ceftazidime/avibactam 452 
Isolate No. Species 
Mech-
anism Parent MIC (mg/L) Initial 
count 
X 109 
Selection frequency x 10-9 using  
   CAZ-AVI 1 at MIC multiple CAZ-AVI 4 at MIC multiple 
   CAZ 
CAZ-
AVI 1  
CAZ-
AVI 4  
 2 x  4 X  8 X  16 X   2 x  4 X  8 X  16 X  
Mei 633 K. pneumoniae SHV-2 >256 4 1 1.11 < < < < 1.8 < < < 
Mei 838 K. pneumoniae SHV-2 64 4 0.5 1.23 8.9 < < < 3.3 < < < 
Mei 254 K. pneumoniae SHV-5 256 4 0.5 1.10 57.4 < < < 1020.0 16.4 < < 
Mei 679 K. pneumoniae SHV-5 >256 4 1 1.63 < < < < < < < < 
LN01001 K. pneumoniae CTX-M-1 64 0.5 0.5 1.46 2.7 < < < < < < < 
LN01028 K. pneumoniae CTX-M-1 256 2 0.5 1.41 2.9 < < < < < < < 
EO 553 E. coli CTX-M-15 16 0.5 0.25 1.27 3.2 < < < 0.8 < < < 
EO 499 E. coli CTX-M-15 32 0.25 0.25 0.92 1.1 < < < < < < < 
NCTC13352 E. coli TEM-10 >256 2 0.5 1.04 183.9 < < < 28.7 < < < 
J53 TEM-10 E. coli TEM-10 >256 2 1 1.22 26.3 1.7 < < 18.9 6.6 < < 
LN03019 E. cloacae AmpC SDR 64 1 0.5 1.51 26.6 < < < < < < < 
LN07047 E. cloacae AmpC SDR 64 1 0.5 1.04 835.6 7.7 1.0 1.9 21.2 4.8 1.9 < 
LN10061 C. freundii AmpC SDR 256 2 1 1.13 < < < < < < < < 
SE01073 C. freundii AmpC SDR 128 1 0.5 0.91 25.3 7.7 3.3 < 8.8 2.2 2.2 < 
LN01QC09 E. coli CAZ S 0.125 0.125 0.125 1.10 Cont. < < < < < < < 
LN04QC03 E. coli CAZ S 0.125 0.125 0.125 1.01 Cont. < < < 13.9 < < < 
LN07013 E. cloacae CAZ S 0.5 0.25 0.25 1.60 267.8 14.4 < < 1.3 < < < 
LN09063A E. cloacae CAZ S 0.25 0.25 0.25 1.63 0.6 < < < < < < < 
Mei 60 K. pneumoniae CAZ S 0.12 0.12 0.12 1.14 3.5 < < < < < < < 
Mei 888 K. pneumoniae CAZ S 0.12 0.12 0.25 1.40 982.8 22.9 < < 0.7 < < < 
 453 
<: Below detection limit of c. 0.5 x10-9 454 
Abbreviations: CAZ, ceftazidime, CAZ-AVI1 ceftazidime with 1 mg/L avibactam; CAZ-AVI4 ceftazidime with 4 mg/L avibactam; Cont: contaminated; CAZ-S 455 
ceftazidime-susceptible; SDR, stably derepressed 456 
  457 
Table 2.  Characterisation of mutants selected from AmpC derepressed E. cloacae and C. freundii  458 
Strain/mutant 
and selection 
conditions  AmpC mutationa Porin status  Other  MIC (mg/L) 
    Ceftazidime  Ceftaroline Others 
    
Alone 
+Avi, 
1 
 mg/L 
+Avi, 
4  
mg/L 
+Clox 
100  
mg/L 
+Clav 
4  
mg/L 
+Taz 
4  
mg/L 
Alone 
+Avi, 
4  
mg/L 
CTX CPM PTZ MEM ERP GEN CIP 
E. cloacae 
LN07047 
  
OmpC/F 
functional 
  128 1 0.5 2 128 64 >32 0.5 256 0.5 64 0.06 0.5 0.5 0.015 
Mutant 4 
(CAZ2-AVI 1) 
Gly176Arg Unchanged  
>256 256 64 >256 >256 >256 >32 2 >256 2 16 0.03 0.25 0.5 0.015 
Mutant 7 
(CAZ4-AVI1) 
Gly176Asp Unchanged  
128 32 16 128 256 128 >32 2 64 0.125 8 0.03 0.06 0.5 0.015 
Mutant 15 
(CAZ1-AVI4) 
Deletion 
Leu313, Ala314 
Unchanged 
OppB  
oligopeptide/ 
nickel transporter  
Tyr272Asp 
256 16 8 8 256 128 16 1 16 16 32 0.03 0.125 0.5 0.015 
Mutant 19 
(CAZ2-AVI4) 
Arg168Pro Unchanged  16 16 16 16 64 32 4 2 2 2 8 0.03 0.03 0.5 0.015 
Mutant 24 
(CAZ4-AVI4) 
Arg168Pro Unchanged  16 16 16 16 32 32 2 2 0.5 2 8 0.03 0.03 0.5 0.03 
C. freundii 
SE01073 
 
OmpF inactivated 
(IS) 
 128 1 0.5 2 128 64 32 0.125 32 1 64 0.06 0.25 0.5 0.015 
Mutant 5 
(CAZ2-AVI1) 
Arg168Pro Unchanged  16 32 8 32 32 32 0.5 0.25 2 4 16 0.015 0.015 1 0.008 
Mutant 8 
(CAZ4-AVI) 
Deletion309-312 
Ser-Lys-Val-Ala; 
Leu313Met 
Unchanged  256 32 8 128 256 256 8 0.25 8 4 64 0.03 0.03 
1 
 
 
0.008 
Mutant 9 
(CAZ4-AVI1) 
Arg168His Unchanged  256 32 4 128 256 256 32 0.25 32 16 64 0.03 0.06 1 0.008 
Mutant 12 
(CAZ8-AVI1) 
Asn366Tyr Unchanged 
DnaK Molecular 
chaperone 
Leu273Gln 
128 64 16 64 128 128 16 2 16 4 64 0.03 0.03 1 0.03 
Mutant 22 
(CAZ4-AVI4) 
Arg168His Unchanged 
Aldehyde 
dehydrogenase 
Arg407His 
128 64 32 64 256 128 16 2 16 4 64 0.03 0.03 1 0.015 
 459 
Parent strains are shown in bold font 460 
a Numbering here is from the first amino acid of the coding sequence as in figure 3 of ref 19.  The first 20 amino acids comprise a signal peptide, cleaved from the mature 461 
protein and are discounted in some numberings  462 
Table 3.  Characterisation of mutants selected from ESBL producers 463 
 MICs (mg/L) 
Strain and 
selective 
conditions 
-
lactamase(s) 
Porin statusa Effluxa Othera Ceftazidime Ceftaroline others 
     Alone 
+Avi, 
1 
mg/L 
+Avi, 
4 
mg/L 
+Clox 
100 
mg/L 
+Clav 
4 
mg/L 
+Taz 
4 
mg/L 
Alone 
+Avi, 
4 
mg/L 
CTX CPM PTZ MEM ERP GEN CIP 
E. coli EO 499 
CTX-M-15, 
OXA-1. 
TEM-1 
OmpC OmpF 
both active 
  32 0.25 0.125 32 0.25 0.5 >32 0.03 256 16 16 0.03 0.06 1 >16 
Mutant 1  
CAZ1-AVI1b 
blaCTX-M-15 up 
from c. 5 to 
40 copies; 
blaTEM/blaOXA 
unchanged 
   >256 2 0.5 >256 2 32 >32 0.06 >256 >64 >256 0.125 0.5 1 >16 
E. coli EO 553  
OmpC OmpF 
both active 
  32 0.5 0.25 32 1 1 >32 0.06 256 32 4 0.03 0.06 0.5 >16 
Mutant 2 
CAZ1-AVI1 
  
AcrB 
Phe615Ser 
 64 2 2 64 2 4 >32 0.125 >256 64 0.5 0.03 0.06 1 >16 
Mutant 3 
CAZ1-AVI1 
CTX-M-15 
Asp182Tyr 
   16 8 2 16 8 16 0.5 0.125 0.5 0.25 4 0.03 0.03 1 >16 
Mutant 5 
CAZ0.5-AVI4 
 
EnvZ : 
Val132Gly 
AcrB 
Phe615Ser 
 64 4 4 64 4 4 >32 0.5 >256 64 0.5 0.06 0.06 0.5 >16 
K. 
pneumoniae 
Mei 838 
SHV-2 
OmpK35, 
OmpK36 both 
active 
  64 2 0.25 64 1 32 >32 0.06 64 16 >256 0.03 0.125 0.5 0.03 
Mutant 6 
CAZ1-AVI4 
blaSHV-2 up 
from c. 15 to 
70 copies 
OmpR:  
Arg15His 
  >256 32 8 >256 8 >256 >32 0.5 >256 >64 >256 0.06 1 1 0.06 
Mutant 7 
CAZ1-AVI4 
blaSHV-2 up 
from c. 15 to 
45 copies 
  
Aspartate-
semialde-
hyde de-
hydrogen-
ase  
>256 32 2 >256 8 >256 >32 0.5 >256 >64 >256 0.06 1 1 0.03 
Gln247Leu 
Mutant 8 
CAZ1-AVI4 
   
4-Cytidine 
5'-
diphospho-
2-C-methyl-
D-erythritol 
kinase   
Ala270Gly 
 
Putative 
sulphate 
transporter 
(ychM)   
Ala99Gly 
>256 32 2 >256 8 >256 >32 0.5 256 >64 >256 0.06 0.5 1 0.06 
Mutant 9 
CAZ1-AVI4 
   
Penicillin 
binding 
protein 2 
mdrA:  
Asp354Ala 
>256 16 8 >256 8 256 >32 0.5 >256 >64 >256 0.06 0.5 1 0.06 
K. 
pneumoniae 
LN01028 
CTX-M-15 
OmpK35, 
OmpK36 both 
active 
  256 1 0.5 256 16 8 >32 0.125 256 64 32 0.125 2 >32 2 
    Mutant 1 
CAZ4-AVI1   
 
EnvZ : 
Arg397Cys 
  >256 16 4 >256 4 >256 >32 0.125 >256 64 >256 0.06 0.5 >32 4 
      Mutant 2 
CAZ4-AVI1   
   
Peptido-
glycan-
associated 
outer 
membrane 
lipo-protein  
Met1Ileu 
>256 16 4 >256 8 >256 >32 0.25 >256 >64 >256 0.06 0.5 >32 4 
Mutant 4 
CAZ4-AVI1 
 
EnvZ : 
Ileu412Leu 
  >256 16 4 >256 4 >256 >32 0.125 >256 >64 >256 0.06 0.5 >32 4 
K. 
pneumoniae 
Mei 254  
SHV-5 
OmpK35, 
OmpK36 both 
active 
  256 1 0.25 256 0.5 2 8 0.125 16 2 8 0.03 0.06 0.5 1 
Mutant 7 
CAZ1-AVI4 
    >256 32 8 >256 8 >256 >32 0.25 256 >64 >256 0.125 1 0.5 1 
Mutant 14 
CAZ2-AVI4 
   
DNA-binding 
protein HLP-
II pleiotropic 
regulator 
Ser2Arg 
>256 16 4 >256 4 >256 >32 0.25 128 32 >256 0.125 1 0.5 1 
E. coli NCTC 
13352 
 
TEM-10 
OmpC, OmpF 
both active 
  >256 1 0.5 256 0.5 2 >32 0.06 1 1 4 0.03 0.03 0.5 0.015 
Mutant 9 
CAZ1-AVI4 
blaTEM copy 
number up 
from 80 to 
200 
EnvZ 
Gln115Arg 
  >256 16 8 >256 8 >256 >32 0.25 32 >64 >256 0.125 1 1 0.03 
Mutant 10 
CAZ1-AVI4 
blaTEM copy 
number up 
from 80 to 
160 
EnvZ 
Gln115Arg 
  >256 16 4 >256 4 128 >32 0.125 16 32 >256 0.06 0.25 1 0.015 
E. coli J53 
TEM-10 
TEM-10 
OmpC, OmpF 
both active 
  >256 1 0.5 256 0.5 2 32 0.06 1 1 4 0.03 0.03 0.5 0.015 
Mutant 2 
CAZ4-AVI1 
Mutation 
upstream of 
blaTEM (-548) 
regulatory 
region 
possibly 
Affecting 
expression? 
   >256 16 4 >256 4 256 >32 0.125 32 >64 >256 0.06 0.25 1 0.015 
Mutant 3 
CAZ4-AVI1 
Mutation 
upstream of 
blaTEM (-548) 
regulatory 
region 
possibly 
Affecting 
expression? 
   >256 16 4 >256 4 >256 >32 0.25 32 >64 >256 0.06 0.25 0.5 0.015 
Mutant 4 
CAZ4-AVI1 
Mutation 
upstream of 
blaTEM (-548) 
regulatory 
region 
possibly 
Affecting 
expression? 
   >256 16 4 >256 4 >256 >32 0.125 32 >64 >256 0.06 0.25 0.5 0.015 
   Mutant  5 
CAZ4-AVI1 
Mutation 
upstream of 
blaTEM (-548) 
regulatory 
region 
possibly 
Affecting 
expression? 
EnvZ : 
Leu35Gln 
  >256 32 16 >256 16 >256 >32 0.5 32 >64 >256 0.25 2 1 0.03 
 464 
Abbreviations: Avi, avibactam; Clav, clavulanate; CP, ciprofloxacin; CTX, cefotaxime, Ert, ertapenem, GENT, gentamicin; MEM, meropenem; PTZ, piperacillin/tazobactam 465 
and Taz, tazobactam 466 
a  Numbering is from the first  amino acid of the coding sequence, irrespective of whether this is cleaved as a signal peptide 467 
 468 
b Selective conditions, CAZ 1 AVI1 means ceftazidime 1 mg/L plus avibactam 1 mg/L  469 
Parent strains are shown in bold font 470 
